Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Preclinical and clinical pharmacology of the GABAA receptor α5 subtype-selective inverse agonist α5IA

Atack, John R. ORCID: https://orcid.org/0000-0002-3410-791X 2010. Preclinical and clinical pharmacology of the GABAA receptor α5 subtype-selective inverse agonist α5IA. Pharmacology and Therapeutics 125 (1) , pp. 11-26. 10.1016/j.pharmthera.2009.09.001

Full text not available from this repository.

Abstract

α5IA is a triazolophthalazine that selectively attenuates the effects of GABA at GABAA receptors containing an α5 subunit. It enhances long-term potentiation in an in vitro model of mouse hippocampal synaptic plasticity, gives good in vivo receptor occupancy and improves cognitive performance in normal rats as measured using the delayed-matching-to-place version of the Morris water maze yet, importantly, it is without anxiogenic or proconvulsant liabilities. The hydroxymethyl isoxazole metabolite, which occurs both in vitro and in vivo, has a very low aqueous solubility (0.6 μg/mL) that resulted in renal toxicity (crystal formation) at very high doses in preclinical safety and toxicity studies. Although this precluded it from being dosed to humans over prolonged periods of time, α5IA is, nevertheless, well tolerated in young and elderly subjects up to a dose of 6 mg in multiple-dose studies and gives a plasma EC50 for α5IA occupancy measured using [11C]flumazenil PET of 10 ng/mL. The compound was evaluated in experimental studies and although in elderly subjects α5IA does not improve performance in a paired-associate learning task (a 4-mg dose actually impairs performance), it is able to reverse the ethanol-induced impairment in performance in healthy young normal volunteers. These data demonstrate that in man an α5-selective inverse agonist may be effective at increasing performance under certain conditions. Whether or not such a compound has efficacy in conditions associated with cognitive deficits, such as attention-deficit hyperactivity disorder, Alzheimer's disease or schizophrenia remains to be determined.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Biosciences
Publisher: Elsevier
ISSN: 0163-7258
Last Modified: 03 Nov 2022 09:45
URI: https://orca.cardiff.ac.uk/id/eprint/105903

Citation Data

Cited 96 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item